Изработка на уеб сайт от Web IT Solutions



Visit website

Portfolio company


Sector: Medical Devices & Diagnostics

A liver disease diagnostics company commercialising new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis.

Exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals.

Tests revolutionise care and treatment for the at-risk, chronic liver disease population.

Located in the USA.


Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. It should be done only as part of a diversified portfolio. Any investments are targeted exclusively at investors who understand the risks of investing in early-stage businesses and can make their own investment decisions. Any pitches for investment are not offers to the public. Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk


Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.